Beyond Air
Garden City, United States · Biotechnology, Healthcare, Health Care · 66 employees
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neona
Funding history
- Funding Round — $32.0M — Nov 2025
- Funding Round — $20.6M — Oct 2024
- Funding Round — $128K — Jul 2024
- Series seed — $1.4M — Jun 2023
- Funding Round — $40.0M — Jun 2023
Recent signals
- Dec 30, 2025: Beyond Air Appoints Dan Moorhead as Chief Financial Officer
- Dec 08, 2025: SEC 8-K (2.01): On January 13, 2026, Beyond Air, Inc. announced that XTL Biopharmaceuticals Ltd. has entered into a binding letter of intent to acquire Beyond Air's 85% ownership interest in NeuroNOS Ltd. This acquisition includes compensation to Beyond Air comprising 19.9% of XTL's issued share capital, $1 million in cash, and potential milestone-based contingent payments totaling up to $31.5 million. NeuroNOS is a biotechnology company focused on developing therapeutics targeting Autism Spectrum Disorder and neuro-oncology. The transaction marks a significant strategic partnership aimed at advancing developments in these critical areas.
- Nov 05, 2025: Raised $32.0M
- Dec 02, 2024: Launched Beyond Air, Inc. announces CE mark approval for LungFit® PH System aimed at improving patient outcomes in Europe.
- Oct 11, 2024: Raised $20.6M
- Sep 27, 2024: Beyond Air Terminates Loan and Security Agreements with Avenue Capital and Enters $11.5 Million Loan Agreement
- Jul 09, 2024: Raised $128K
- Jun 14, 2024: Beyond Air, Inc. Appoints David Webster as Chief Commercial Officer
See plans & pricing → Track Beyond Air’s funding, hiring, and signals — with verified contacts — on Fundz.